anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic rhinosinusitis (CRS) is an inflammatory condition of the lining of the nose and sinuses that lasts 12 weeks or longer with objective evidence of mucosal inflammation (1). CRSwNP is characterized by the presence of bilateral nasal polyps in the middle meatus. Patients with CRSwNP for whom medical therapy has failed, often have functional endoscopic sinus surgery.

Nasal steroids are important post-operatively to prevent polyps from recurring. Many studies have shown that nasal steroids are superior to placebo in maintaining improvement in symptom scores, such as SNOT-22, post-operatively by preventing polyps from returning (2). Nasal steroids can reduce inflammation locally and can prevent disease relapse without the systemic effects of oral steroids. However, there is no consensus as to which nasal steroid and which delivery method is most effective in treating these patients. Traditional nasal sprays, such as fluticasone spray, may not deliver the medication widely in the nasal cavity. Budesonide is available in a respule form that can be used to instill the medication in the nose. In an attempt to more effectively deliver the medication, changes in patient's head position has been prescribed to achieve better delivery (3). The safety of intranasal budesonide, a more potent steroid than fluticasone, has been established (4, 5). However, any improved efficacy over fluticasone nasal spray remains anecdotal as head to head comparisons have not previously been performed.

Practice patterns among rhinologists in the post-operative prescription of nasal steroids vary widely. Determining which medication/delivery method is more effective will help rhinologists better treat their patients and prevent symptoms, for which the surgery was performed, from returning.
Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative effectiveness has been confirmed. Accordingly, the present invention provides Diquafosol ophthalmic solution having physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient. Particularly in the course of production, the solution can be subjected to efficient filtration sterilization. Moreover, the solution has excellent preservative effectiveness. The present invention also provides a method for inhibiting formation of insoluble precipitates from an aqueous ophthalmic solution comprising diquafosol or a salt thereof, by adding a chelating agent to the solution.
PURPOSE: To crystallize a cyclic lipopeptide efficiently useful as an antifungal agent, etc., against Candida species by solubilizing the lipopeptide in warm aqueous n-propanol soln., allowing the soln. obtd. to stand for a time sufficient to complete crystalline formation at room temp.  
     CONSTITUTION: A medium is inoculated with Zalerion arboricola MF 5533 (ATCC 74030), cultured while shaking at 25°C for four days. The culture is collected and used to inoculate a seed bacterium fermenter and the seed bacterium broth, prepd. by culturing in the fermenter at 25°C for six day, is used to inoculate a medium in a production fermenter. After the medium is cultured aerobically in pH of 6.0 at 25°C, the broth obtd. from the culture is extracted into methanol. The extract is passed through a brominated styrene- divinylbenzene copolymer absorption column, the absorbent is eluted, purified to obtain a lipopeptide represented by formula. This is dissolved into aqueous n-propanol soln. and the soln. obtd. is allowed to stand for a time sufficient to complete crystalline formation at a room temp. to crystallize, and the cyclic peptide of formula is obtd. by separating the crystalline produced. 
     COPYRIGHT: (C)1993,JPO
As the body's largest organ, the skin is located at the internal and external environment interface, serving as a line of defense against various harmful stressors. Recently, marine-derived physiologically active ingredients have attracted considerable attention in the cosmeceutical industry due to their beneficial effects on skin health. Sargassum, a genus of brown macroalgae, has traditionally been consumed as food and medicine in several countries and is rich in bioactive compounds such as meroterpenoids, sulfated polysaccharides, fucoidan, fucoxanthin, flavonoids, and terpenoids. Sargassum spp. have various beneficial effects on skin disorders. They help with atopic dermatitis by improving skin barrier protection and reducing inflammation. Several species show potential in treating acne by inhibiting bacterial growth and reducing inflammation. Some species, such as Sargassum horneri, demonstrate antiallergic effects by modulating mast cell activity. Certain Sargassum species exhibit anticancer activity by inhibiting tumor growth and promoting apoptosis, and some species help with wound healing by promoting angiogenesis and reducing oxidative stress. Overall, Sargassum spp. demonstrate potential for treating and managing various skin conditions. Therefore, the bioactive compounds of Sargassum spp. may be natural ingredients with a wide range of functional properties for preventing and treating skin disorders. The present review focused on the various biological effects of Sargassum extracts and derived compounds on skin disorders.
Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
PURPOSE:To provide a tablet or granule capable of readily polished, having a new glassy luster, free from the anxiety about remained solvents, capable of being applied even to thermally unstable drugs and having a beautiful appearance and a high commercial value. CONSTITUTION:A tablet or granule, especially the tablet or granule coated with a coating soluble in a gastric juice or intestinal juice or with a sustained- release coating, is coated with a chitosan solution to provide the tablet or granule having the above-mentioned effects. The coating solution is prepared by dissolving the chitosan in diluted acetic acid or sulfuric acid. The concentration of the chitosan depends on the polymerization degree of the chitosan, but is suitably approximately 0.1-3.0wt.%. The solution is, if necessary, changed into an organic solvent solution such as a water-alcohol solution. The coating amount is usually 0.01-3.0wt.%, preferably 0.01-1.0wt.%.
The present invention relates to a cell composition comprising neural stem cells, nerve cells, or GABAergic nerve cells differentiated from mesenchymal stem cells. The cell composition comprises: neural stem cells; and at least one of an immature neural stem cells or a mesenchymal stem cell. The cell composition can increase growth, survival rate, and differentiation rate of a cell in an area in which the cell composition is injected. The cell composition can be applied to nerve disease without removal of a cell, which has not been differentiated into a final nerve cell, a nerve cell, or a GABAergic nerve cell. The cell composition can prevent, alleviate, or treat nerve disease in an effective manner. When the cell composition is applied to a human body, the cell composition has a low probability of generating cytotoxicity and thus can be used as a safe cell treatment agent. The cell composition can be applied as an excellent source of a neural stem cell, nerve cell, or GABAergic cell. The cell composition can be used as not only a nerve disease treatment agent but also a cosmetic material composition. The present invention relates to the cell composition comprising neural stem cells, differentiated from mesenchymal stem cells, nerve cells, or GABAergic nerve cells.
The increasing use of medical implants in various areas of medicine, particularly in orthopedic surgery, oncology, cardiology and dentistry, displayed the limitations in long-term integration of available biomaterials. The effective functioning and successful integration of implants requires not only technical excellence of materials but also consideration of the dynamics of biomaterial interaction with the immune system throughout the entire duration of implant use. The acute as well as long-term decisions about the efficiency of implant integration are done by local resident tissue macrophages and monocyte-derived macrophages that start to be recruited during tissue damage, when implant is installed, and are continuously recruited during the healing phase. Our review summarized the knowledge about the currently used macrophages-based in vitro cells system that include murine and human cells lines and primary ex vivo differentiated macrophages. We provided the information about most frequently examined biomarkers for acute inflammation, chronic inflammation, foreign body response and fibrosis, indicating the benefits and limitations of the model systems. Particular attention is given to the scavenging function of macrophages that controls dynamic composition of peri-implant microenvironment and ensures timely clearance of microorganisms, cytokines, metabolites, extracellular matrix components, dying cells as well as implant debris. We outline the perspective for the application of 3D systems for modelling implant interaction with the immune system in human tissue-specific microenvironment avoiding animal experimentation.
Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500 to 20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal hematopoiesis. Genome-first approaches of cohorts linked to phenotype data can further refine these estimates by identifying individuals with variants of interest and then assessing their phenotypes. This study evaluated P/LP germline (variant allele fraction ≥30%) TP53 variants in three cohorts: UK Biobank (UKB, n = 200,590), Geisinger (n = 170,503), and Penn Medicine Biobank (PMBB, n = 43,731). A total of 109 individuals were identified with P/LP germline TP53 variants across the three databases. The TP53 p.R181H variant was the most frequently identified (9 of 109 individuals, 8%). A total of 110 cancers, including 47 hematologic cancers (47 of 110, 43%), were reported in 71 individuals. The prevalence of P/LP germline TP53 variants was conservatively estimated as 1:10,439 in UKB, 1:3,790 in Geisinger, and 1:2,983 in PMBB. These estimates were calculated after excluding related individuals and accounting for the potential impact of clonal hematopoiesis by excluding heterozygotes who ever developed a hematologic cancer. These varying estimates likely reflect intrinsic selection biases of each database, such as healthcare or population-based contexts. Prospective studies of diverse, young cohorts are required to better understand the population prevalence of germline TP53 variants and their associated cancer penetrance.
We aimed to summarize the surgical treatment for pharyngolaryngeal stenosis and discuss prognosis in patients with Behcet's disease. Six cases of pharyngolaryngeal stenosis caused by Behcet's disease were analyzed retrospectively. All underwent surgical treatment for pharyngolaryngeal stenosis after systematic medical treatment. The follow-up time for the 6 patients was between 1 and 12 years. Four of the 6 patients underwent adhesiolysis as their first procedure. Two of these 4 experienced recurrence of stenosis within 6 months and underwent flap repair as their second procedure. The remaining two patients underwent flap reconstruction as their first procedure and maintained good swallowing function. Three of the 6 patients underwent preoperative tracheotomy because of dyspnea. Tracheal decannulation was successful in all patients. None of the patients experienced recurrence after their final surgical procedure and all recovered to a near-normal condition. Pharyngolaryngeal stenosis caused by Behcet's disease is a rare but severe complication; surgical intervention should be considered in patients with dysphagia after systematic medical treatment.
Five pharmaceutical inventions are synthesized by administering metallic substances, preferably immunoactive copper in the form of tyrosinase, with the optional use of a composition consisting of CoEnzyme Q1 to Q10, a multivitamin, and amino acids. The composition artificially maintains the presence of metallic substances beyond normal metabolism time in the tissues, organs, arteries, veins or body fluids of humans, animals, agricultural plant fibers, leafs, or root systems. The initialization of therapy utilizes radiological, X-Ray, MRI, PET or ultrasonic imaging to establish maximum dilation, followed by a micromolar metallic assay, such that continued dosages are administered to maintain the static proportional micromolar amount of the metal in the blood and urine. Five embodiments: (1) Immunoamplification by dilation of the thymus. (2) Immunoamplification by ingestion of enriched agricultural plants. (3) Prebirth Immunoamplification for poultry eggs. (4) A vasodilative treatment for seizures, spasms, excessive EEG pulses, epilepsy, vasoconstrictive headaches, tourette's syndrome, or any disorder resulting from low brain copper levels. (5) A method to reclassify plants, based on the distribution of metals to determine suitability as immunoamplification agents. Typical Immunoamplification uses: presurgical treatment for donor/acceptor organ transplant, AIDS, HIV, or, to increase the T-Lymphocyte helper cells.
Upwards of 40% of children and adolescents/young adults (AYAs) in the United States suffer from at least one chronic medical condition, excluding obesity. The emotional and psychological burden of having a chronic condition in youth can lead this population to experience higher rates of stress, depression, and anxiety in addition to reduced health-related quality of life compared to their healthy peers. Acceptance and Commitment Therapy (ACT) is an intervention that teaches skills such as psychological flexibility, mindfulness, and cognitive defusion that has been shown to significantly improve psychological outcomes and quality of life among children and AYAs with chronic conditions. Few studies, however, have examined the efficacy of this intervention in reducing stress among children and AYAs with chronic conditions delivered in a group, web-based format. The need for virtually administered psychological interventions is especially salient amidst the Covid-19 pandemic as CDC guidelines discourage in-person gatherings and close contact with others. The current study aims to: 1) Determine if a web-based group ACT intervention of 6 sessions is more effective than no intervention (waitlist control) in reducing stress among children and AYAs with chronic conditions, 2) Determine if a web-based group ACT intervention of 6 sessions is more effective than no intervention in improving other functional outcomes among children and AYAs with chronic conditions, 3) Evaluate if a web-based group ACT intervention of 6 sessions improves participants skills in psychological flexibility, mindfulness, and cognitive defusion. Study population: Children and Adolescents/Young Adults (ages 14-21) diagnosed with a chronic medical condition seeking care at Children's Hospital Los Angeles, who are in the normal range of development and are eligible to participate in the study. Study Methodology: The study is a non-blinded, randomized, controlled trial designed to examine the effect of a web-based group ACT intervention on stress, depression, anxiety, health-related quality of life, and adaptive psychological skills in children and AYAs with chronic conditions. Statistical analysis: The primary analysis will involve a two independent samples t-test to compare the mean 6-week PSS scores between the two treatment groups. Secondary analyses will compare treatment groups on other study outcomes.
This proof-of-concept study is a double-blind, randomized, placebo-controlled, parallel-group, single-site study designed to assess the feasibility, acceptability, and tolerability of atomoxetine for alcohol use disorder among adolescents ages 14 to 19 years. In addition, this project will test the effects of atomoxetine, as compared with placebo, on responses to in vivo alcohol cue exposure in the human laboratory setting. After obtaining consent/parent permission/assent, youth and, if younger than 18 years, their parent will complete a medical history interview to screen for eligibility. Youth will also be screened for eligibility. If eligible for the study, participants will be randomized in an approximate 1:1 ratio (targeting 21 participants per group - 42 participants total) to either atomoxetine or placebo for 6 weeks. Atomoxetine will be dosed at 40 mg/day for three days then increased to the maintenance dose of 80 mg (active) taken orally once daily (QD) for an additional 5.5 weeks. Participants randomized to the placebo condition will be given an equal number of visually matched capsules.

Participants will be seen in the clinic at the in-person screening appointment, the randomization/baseline session, and at 8 other times during the study. Three follow-up telephone interviews will occur at 2 weeks and three and six months after the last in-clinic visit. At the randomization/baseline visit and after 4 weeks of investigational product administration (i.e., Study Week 7), participants will undergo a human laboratory paradigm (i.e., alcohol cue reactivity assessment). In addition, participants will complete EMA on a smartphone throughout the day in their daily lives.
This study is an international prospective, multi-center, registry study; collecting clinical data regarding standard-of-care use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion. NanoKnife System is a commercially available irreversible electroporation system. Since it is participants who are candidates for or undergo the NanoKnife procedure will be consented to participate in this prospective registry study. Clinical data from enrolled patients will be collected and patients will undergo clinical follow-up at the following time points post-procedure: 24-48 hours post-procedure, hospital discharge, 7 days post-procedure, 30 days, and 90 days. See Appendix 1: Schedule of Events Collected as Part of Study Registry.

Participants will be followed for 4 years following the NanoKnife procedure. While in the hospital, they will be evaluated within 24-48 hours after the NanoKnife procedure. Additional assessments will be performed prior to being discharged from the hospital. Participants will be asked to return every 3 month follow up to 2 years and then every 6 months after 2 years from IRE. Each visit will last approximately two (2) to three (3) hours at the study doctor's clinic. During these visits, participants will also be asked to report any change in their medications. Except for the study visits, they will not need to visit the study doctor more often than their usual treatment unless they have other medical needs. However, if participants experience any significant change in their medical condition they may be asked to have additional tests such as CT scan, blood tests, etc. Participants will not receive any financial or other compensation for taking part in this study.
The present invention relates to a preparation technology and a production method for an integrated new formulation of an aconite decoction, wherein the raw materials of active ingredients comprise: 9 parts by weight of ephedra stem, 9 parts by weight ofastragalus root, 9 parts by weight of peony, 9 parts by weight of honey-fried licorice, 5 parts by weight of Sichuan aconite main root, and 400 parts by weight of honey. The production process of the integrated new formulation of aconite decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of aconite decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of aconite decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of aconite decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
The present inventors developed a glyoxalase (GLO) fusion protein expression vector. This expression vector was used to over-express the GLO fusion protein, which was then purified by using Ni^2+ affinity chromatography columns. Western blotting confirmed that the GLO fusion protein purified in the cultured insulin-secreting cells was delivered to cells in a concentration and time dependent manner. The GLO fusion protein permeating the cells was continuously maintained 48 hours in the cells. In addition, it was seen that the GLO fusion protein permeating the cells effectively inhibited cell death due to sodium nitroprusside (SNP) and DNA fragmentation. It was verified through histological staining, blood glucose level testing, and blood testing, that the GLO fusion protein effectively inhibited diabetes even in a diabetic animal model using streptozotocin (STZ). These results mean that the GLO fusion protein permeates the insulin-secreting cells and the GLO function is well conducted in the cells. Therefore, the GLO fusion protein can be applied as an agent for treating diabetic diseases and diabetic complications.
Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.